ClinicalTrials.gg
CompletedNCT02458014Updated Sep 25, 2026Results posted

Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease

A Phase 2 interventional study of Blinatumomab and TKI in Adult Acute Lymphoblastic Leukemia in Complete Remission, B Acute Lymphoblastic Leukemia and Minimal Residual Disease, sponsored by M.D. Anderson Cancer Center. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by M.D. Anderson Cancer Center · Phase 2, Interventional, and Treatment

How we know

Updated Sep 25, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
37
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 35 studies testing blinatumomab in Burkitt Lymphoma — 16 open to participants now, 23 under way, 8 of them phase 3. blinatumomab · Burkitt Lymphoma.

Enrollment
20th of 35
37 · median 52
Started
2015
the only one that year
Phase 2
17 of 35
8 open now
Registered
5th of 35
by date
Lead sponsor
5 of 35
M.D. Anderson Cancer Center

Among the 35 studies testing blinatumomab in Burkitt Lymphoma, this one is the 20th largest by enrollment, is the only one that started in 2015, is one of 17 in phase 2, and was the 5th registered.

Burkitt Lymphoma

978 studies on the registry are indexed under Burkitt Lymphoma; 160 are open to participants now.

Browse Burkitt Lymphoma studies →

Open to participants now

16 of the 35 studies testing blinatumomab in Burkitt Lymphoma are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About blinatumomab

blinatumomab: first FDA approval 2014 (BLINCYTO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 132 Burkitt Lymphoma studies recruiting now, 41 (31%) set no upper age limit and 78 (59%) stop at 75 or younger; 75 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies testing blinatumomab in Burkitt Lymphoma, or all of them as a file.
02

Study summary

This phase II trial studies how well blinatumomab works in treating patients with B-cell acute lymphoblastic leukemia whose disease is in remission (causes no symptoms or signs) but is still present in a small number of cells in the body (minimal residual disease). Immunotherapy with monoclonal antibodies, such as blinatumomab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread.

Read the detailed description

PRIMARY OBJECTIVES:

I. To evaluate the clinical efficacy of blinatumomab in patients B-cell acute lymphoblastic leukemia in complete morphologic remission with positive minimal residual disease (MRD) in terms of relapse-free survival (RFS).

SECONDARY OBJECTIVES:

I. To evaluate other efficacy endpoints such as overall survival and MRD negativity rate by flow cytometry and/or polymerase chain reaction (PCR) overall and after the first cycle, as well as safety of blinatumomab in this setting.

OUTLINE:

Patients receive blinatumomab intravenously (IV) continuously on days 1-28. Treatment repeats every 6 weeks for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients who do not proceed with stem cell transplantation may receive blinatumomab IV maintenance therapy with one cycle every 3 months for up to 4 cycles. Patients who remain in MRD remission for 3 months and then become MRD positive again can be retreated following the same treatment plan previously received.

After completion of study treatment, patients are followed up every 6 months.

03

Conditions studied

  • Adult Acute Lymphoblastic Leukemia in Complete Remission
  • B Acute Lymphoblastic Leukemia
  • Minimal Residual Disease
  • Philadelphia Chromosome Positive
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with B-lineage acute lymphocytic leukemia (ALL) in hematologic complete remission (CR) with molecular failure (i.e., had never achieved an MRD-negativity status before blinatumomab) or had a molecular relapse (i.e., became MRD positive after having been MRD negative) starting at any time point after 3 months of frontline therapy; molecular disease or minimal residual disease is defined by a value of at least of 1 x 10\^-4 (0.01%) by multicolor flow cytometry and/or by next generation sequencing (NGS)
  • Patients with B-lineage ALL in hematologic complete remission (CR) with molecular failure (i.e., had never achieved an MRD-negativity status before blinatumomab) or had a molecular relapse (i.e., became MRD positive after having been MRD negative) starting at any time point after 3 months of frontline therapy; molecular disease or minimal residual disease is defined by a value of at least of 1 x 10-4 (0.01%) by multicolor flow cytometry and/or by next generation sequencing (NGS)
  • Performance status of 0, 1, or 2
  • >= 30 ml/minute
  • less than or equal to 3.0 mg/dL
  • No active or co-existing with less than 12 months
  • Patients with Philadelphia chromosome positive (Ph+) ALL can be enrolled in CR1 or CR2 and beyond; a tyrosine kinase inhibitor (TKI) will be added at the discretion of the treating physician; MRD for these patients will be defined by PCR of 0.1% and above (International Scale)

Exclusion criteria

Exclusion Criteria:

  • Pregnant or nursing women
  • Known to be positive (HIV+)
  • Active and uncontrolled disease/infection as judged by the treating physician
  • Unable or unwilling to sign the consent form
  • Active central nervous system (CNS) or extramedullary disease
  • Monoclonal antibodies therapy within 2 weeks before study entry
  • Radiotherapy and cancer chemotherapy (except for intrathecal prophylaxis and/or low-dose maintenance therapy such as vinca alkaloids, mercaptopurine, methotrexate, ) or any drug within 2 weeks before study entry
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    Treatment (blinatumomab)

    Patients receive blinatumomab IV continuously on days 1-28. Treatment repeats every 6 weeks for up to 5 courses in the absence of disease progression or unacceptable toxicity. Patients who do not proceed with stem cell transplantation may receive blinatumomab IV maintenance therapy with one cycle every 3 months for up to 4 cycles. Patients who remain in MRD remission for 3 months and then become MRD positive again can be retreated following the same treatment plan previously received.

    Biological: Blinatumomab

  • Experimental
    Treatment (blinatumomab + TKI)

    Patients receive blinatumomab IV continuously on days 1-28. Treatment repeats every 6 weeks for up to 5 courses in the absence of disease progression or unacceptable toxicity. Patients who do not proceed with stem cell transplantation may receive blinatumomab IV maintenance therapy with one cycle every 3 months for up to 4 cycles. Patients who remain in MRD remission for 3 months and then become MRD positive again can be retreated following the same treatment plan previously received. A TKI will be added at the discretion of the treating physician.

    Biological: Blinatumomab · Other: TKI

Interventions

  • BiologicalBlinatumomab

    Given IV

    Also known as: Anti-CD19 x Anti-CD3 Bispecific Monoclonal Antibody, Anti-CD19/Anti-CD3 Recombinant Bispecific Monoclonal Antibody MT103, Blincyto, MEDI-538, MT-103

  • OtherTKI

    A TKI will be added at the discretion of the treating physician.

06

What researchers measure

Primary outcomes

  1. Relapse-free Survival (RFS)

    RFS is relapse-free survival, which is defined as the time interval from date of treatment start until the date of death or hematologic or extramedullary disease relapse. Patients who are alive and relapsefree at the last follow-up date will be censored at that time. In addition, patients who drop off the study due to receiving allogeneic stem cell transplantation will be censored at the time off study.

    Time frame: From the date of treatment start until the date of death, relapse or discontinuation due to receiving allogeneic stem cell transplantation, assessed up to 112 months.

Secondary outcomes

  1. Overall Survival (OS)

    Time from date of treatment start until date of death due to any cause.

    Time frame: From treatment start to the date of death or last follow-up, whichever occurred first, Up to 10 years, and 1 day

  2. Number of Patients MRD Negative Overall

    MRD negativity is defined as undetectable MRD by flow cytometry with a sensitivity of at least 10\^-4. For patients with Ph+ ALL, MRD negativity is defined as undetectable MRD by flow cytometry with a sensitivity of at least 10\^-4 AND absence of a quantifiable PCR for BCR-ABL1 by PCR with a sensitivity of at least 10\^-4 or a ratio of BCR-ABL1 to ABL1 by PCR of \< 0.01% according to the International Scale for patients with p210 transcript or a ratio of BCR-ABL1 to ABL1 by PCR of \< 0.01% for patients with non-p210 transcripts

    Time frame: Up to 10 years and 1 day

  3. Number of Participants Who Were MRD Negative After Course 1

    MRD negativity is defined as undetectable MRD by flow cytometry with a sensitivity of at least 10\^-4. For patients with Ph+ ALL, MRD negativity is defined as undetectable MRD by flow cytometry with a sensitivity of at least 10\^-4 AND absence of a quantifiable PCR for BCR-ABL1 by PCR with a sensitivity of at least 10\^-4 or a ratio of BCR-ABL1 to ABL1 by PCR of \< 0.01% according to the International Scale for patients with p210 transcript or a ratio of BCR-ABL1 to ABL1 by PCR of \< 0.01% for patients with non-p210 transcripts

    Time frame: Up to 6 weeks

07

Results

Posted Sep 25, 2026

Participant flow

Participant flow — Overall Study
MilestoneTreatment (Blinatumomab)Treatment (Blinatumomab + TKI)
Started1918
Completed1918
Not completed00

Outcome measures

PrimaryRelapse-free Survival (RFS)

RFS is relapse-free survival, which is defined as the time interval from date of treatment start until the date of death or hematologic or extramedullary disease relapse. Patients who are alive and relapsefree at the last follow-up date will be censored at that time. In addition, patients who drop off the study due to receiving allogeneic stem cell transplantation will be censored at the time off study.

Time frame:
From the date of treatment start until the date of death, relapse or discontinuation due to receiving allogeneic stem cell transplantation, assessed up to 112 months.
Reported as:
Median · Months
Relapse-free Survival (RFS)
MonthsTreatment (Blinatumomab)Treatment (Blinatumomab + TKI)
Relapse-free Survival (RFS)11.6 (0.9 to 110.4)25.0 (1.4 to 81.5)
SecondaryOverall Survival (OS)

Time from date of treatment start until date of death due to any cause.

Time frame:
From treatment start to the date of death or last follow-up, whichever occurred first, Up to 10 years, and 1 day
Reported as:
Median · Months
Overall Survival (OS)
MonthsTreatment (Blinatumomab)Treatment (Blinatumomab + TKI)
Overall Survival (OS)60.8 (3.6 to 116.0)NA (5.1 to 104.5)
SecondaryNumber of Patients MRD Negative Overall

MRD negativity is defined as undetectable MRD by flow cytometry with a sensitivity of at least 10\^-4. For patients with Ph+ ALL, MRD negativity is defined as undetectable MRD by flow cytometry with a sensitivity of at least 10\^-4 AND absence of a quantifiable PCR for BCR-ABL1 by PCR with a sensitivity of at least 10\^-4 or a ratio of BCR-ABL1 to ABL1 by PCR of \< 0.01% according to the International Scale for patients with p210 transcript or a ratio of BCR-ABL1 to ABL1 by PCR of \< 0.01% for patients with non-p210 transcripts

Time frame:
Up to 10 years and 1 day
Reported as:
Count of participants · Participants
Number of Patients MRD Negative Overall
ParticipantsTreatment (Blinatumomab)Treatment (Blinatumomab + TKI)
Number of Patients MRD Negative Overall1611
SecondaryNumber of Participants Who Were MRD Negative After Course 1

MRD negativity is defined as undetectable MRD by flow cytometry with a sensitivity of at least 10\^-4. For patients with Ph+ ALL, MRD negativity is defined as undetectable MRD by flow cytometry with a sensitivity of at least 10\^-4 AND absence of a quantifiable PCR for BCR-ABL1 by PCR with a sensitivity of at least 10\^-4 or a ratio of BCR-ABL1 to ABL1 by PCR of \< 0.01% according to the International Scale for patients with p210 transcript or a ratio of BCR-ABL1 to ABL1 by PCR of \< 0.01% for patients with non-p210 transcripts

Time frame:
Up to 6 weeks
Reported as:
Count of participants · Participants
Number of Participants Who Were MRD Negative After Course 1
ParticipantsTreatment (Blinatumomab)Treatment (Blinatumomab + TKI)
Number of Participants Who Were MRD Negative After Course 1159

Adverse events

Collected over Up to 10 years, and 1 day. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment (Blinatumomab)11/19 (57.9%)12/19 (63.2%)10/19 (52.6%)
Treatment (Blinatumomab) + TKI6/18 (33.3%)11/18 (61.1%)12/18 (66.7%)
Most frequent serious events
Showing 10 of 32
Most frequent serious events
EventTreatment (Blinatumomab)Treatment (Blinatumomab) + TKI
FeverGeneral disorders0/195/18
Lung InfectionInfections and infestations1/193/18
CRS: cytokine release syndromeImmune system disorders2/190/18
PAINGeneral disorders2/190/18
Altered Mental StatusNervous system disorders0/191/18
Catheter related infectionInfections and infestations0/191/18
Chest painCardiac disorders0/191/18
ConfusionPsychiatric disorders0/191/18
ConstipationGastrointestinal disorders0/191/18
Enterocolitis infectiousInfections and infestations0/191/18
Most frequent other events
Showing 10 of 62
Most frequent other events
EventTreatment (Blinatumomab)Treatment (Blinatumomab) + TKI
FeverGeneral disorders0/197/18
Abdominal painGastrointestinal disorders0/194/18
ALT increasedInvestigations0/194/18
Creatinine increasedInvestigations0/194/18
DiarrheaGastrointestinal disorders0/193/18
FatigueGeneral disorders0/193/18
Lung InfectionInfections and infestations1/193/18
ConfusionPsychiatric disorders3/192/18
Altered Mental StatusNervous system disorders0/192/18
Back painMusculoskeletal and connective tissue disorders0/192/18

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Treatment (Blinatumomab)Treatment (Blinatumomab) + TKITotal
<=18 years101
Between 18 and 65 years171633
>=65 years123
Age, Continuous
Age, Continuous(years)Treatment (Blinatumomab)Treatment (Blinatumomab) + TKITotal
Median42 (18 to 66)43 (21 to 83)42 (18 to 83)
Sex: Female, Male
Sex: Female, Male(Participants)Treatment (Blinatumomab)Treatment (Blinatumomab) + TKITotal
Female10616
Male91221
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment (Blinatumomab)Treatment (Blinatumomab) + TKITotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American145
White151227
More than one race000
Unknown or Not Reported325
Region of Enrollment
Region of Enrollment(participants)Treatment (Blinatumomab)Treatment (Blinatumomab) + TKITotal
United States191837
08

Study locations

1 site
  • M D Anderson Cancer Center
    Houston, Texas 77030, United States
09

References and documents

Publications

  • Jabbour EJ, Short NJ, Jain N, Jammal N, Jorgensen J, Wang S, Wang X, Ohanian M, Alvarado Y, Kadia T, Sasaki K, Garris R, Garcia-Manero G, Ravandi F, Kantarjian HM. Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10-4 and higher. Am J Hematol. 2022 Sep;97(9):1135-1141. doi: 10.1002/ajh.26634. Epub 2022 Jun 24. PubMed 35713551 ↗
  • Shi Z, Zhu Y, Zhang J, Chen B. Monoclonal antibodies: new chance in the management of B-cell acute lymphoblastic leukemia. Hematology. 2022 Dec;27(1):642-652. doi: 10.1080/16078454.2022.2074704. PubMed 35622074 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2015 to primary completion in Sep 2025, 120 months.

Results were first posted in Sep 2026, 1 year after primary completion.

Of 84 non-industry phase 2 interventional studies under Burkitt Lymphoma, half reached primary completion within 83 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 120. This study's 120 months is above that.

Counting every sponsor, half of 92 studies reached it within 81 months; a quarter within 41 and three quarters within 119.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2015
First posted
May 29, 2015
StartActual
Sep 14, 2015
Primary completionActual
Sep 16, 2025
CompletionActual
Sep 16, 2025
Results first posted
Sep 25, 2026
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Sep 25, 2026
Enrollment
36→37
Sep 25, 2026
Interventions
Added TKI; removed Laboratory Biomarker Analysis. Arms added: Treatment (blinatumomab + TKI)
Sep 25, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedRelapse-free survivalSurvival (RFS)Time frame: From date of treatment start until the date of death or hematologic or extramedullary disease relapse, assessed up to 18 months → From the date of treatment start until the date of death, relapse or discontinuation due to receiving allogeneic stem cell transplantation, assessed up to 112 months.
Sep 25, 2026
Documents
Secondary outcomes
2 edited, 1 added, 3 removed
What changed in the outcomes
  • EditedOverall survivalSurvival (OS)Time frame: Up to 18 months → From treatment start to the date of death or last follow-up, whichever occurred first, Up to 10 years, and 1 day
  • EditedNumber of Participants Who Were MRD negativity rate after courseNegative After Course 1Time frame: Up to 6 weeks
  • AddedNumber of Patients MRD Negative OverallTime frame: Up to 10 years and 1 day
  • RemovedEvent-free survivalTime frame: Up to 18 months
  • RemovedMRD negativity rateTime frame: Up to 18 months
  • RemovedIncidence of toxicityTime frame: Up to 18 months
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Results posted
    Enrollment 36→37
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedRelapse-free survivalSurvival (RFS)Time frame: From date of treatment start until the date of death or hematologic or extramedullary disease relapse, assessed up to 18 months → From the date of treatment start until the date of death, relapse or discontinuation due to receiving allogeneic stem cell transplantation, assessed up to 112 months.
    Secondary outcomes 2 edited, 1 added, 3 removed
    What changed in the outcomes
    • EditedOverall survivalSurvival (OS)Time frame: Up to 18 months → From treatment start to the date of death or last follow-up, whichever occurred first, Up to 10 years, and 1 day
    • EditedNumber of Participants Who Were MRD negativity rate after courseNegative After Course 1Time frame: Up to 6 weeks
    • AddedNumber of Patients MRD Negative OverallTime frame: Up to 10 years and 1 day
    • RemovedEvent-free survivalTime frame: Up to 18 months
    • RemovedMRD negativity rateTime frame: Up to 18 months
    • RemovedIncidence of toxicityTime frame: Up to 18 months
    Interventions Added TKI; removed Laboratory Biomarker Analysis. Arms added: Treatment (blinatumomab + TKI)
    + 2 other changes: verification date and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT02458014
Responsible party
Sponsor
First posted
May 29, 2015
Start date
Sep 14, 2015
Primary completion
Sep 16, 2025
Completion
Sep 16, 2025
Results posted
Sep 25, 2026
Last update
Sep 25, 2026

Study contacts

Elias Jabbour
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Blinatumomab

Start the discussion